

LONG-TERM PERSISTENCE OF USTEKINUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Gerassimos J. Mantzaris

UEG Week Berlin 2025

Poster

IBD

October 4, 2025

A prospective single-centre study of 52 Crohn's disease patients found 80.7% maintained ustekinumab treatment with clinical, biomarker and endoscopic remission for up to 6 years or more without dose escalation.

KEY POINTS

- Of 52 bio-naive and bio-experienced CD patients who achieved response at 6 months on ustekinumab 90mg sc every 8 weeks, 42 patients (80.7%) remained in remission at follow-up ranging from over 2 years to 6 years or longer.
- At time of reporting, patients in remission had mean HBI 2.3, CRP below 0.5 mg/dL and fecal calprotectin below 200 µg/ml, with no treatment escalation required and no serious adverse events or serious infections reported.
- Ten patients (19.3%) discontinued treatment: 5 due to post-operative endoscopic recurrence, 2 due to colitis flare, 1 due to active axonal spondyloarthritis, and 2 due to cancer diagnoses (pancreatic cancer and colorectal cancer).
- Treatment cessation was statistically higher in bio-experienced patients compared to bio-naive patients ($p < 0.05$).

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/a8280fae-a813-11f0-bead-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.